← All organizations
Highest phase reached
Phase 2
First clinical trial
Nov 1, 2009Last known activity
Aug 1, 2024
Timeline
2000s
- Jun 1, 2008
Adaptimmune— Founded
Drugs by trial phase (16 distinct, 22 trials)
Phase 2 (8 own, 0 via acquisition)
Indications
Studied for
- Carcinoma
- Carcinoma, Hepatocellular
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Ovarian Epithelial
- Carcinoma, Transitional Cell
- Esophageal Neoplasms
- Head and Neck Neoplasms
- HIV Infections
- Liposarcoma
- Liposarcoma, Myxoid
- Liver Neoplasms
- Lung Neoplasms
- Melanoma
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Ovarian Neoplasms
- Sarcoma
- Sarcoma, Synovial
- Urinary Bladder Neoplasms
Recent trials (22)
- NCT06617572Lead sponsorN/A—
- NCT06204991CollaboratorPhase 1Mar 1, 2024
- NCT05642455Lead sponsorPhase 1/Phase 2May 1, 2023
- NCT05601752Lead sponsorPhase 2Dec 4, 2022
- NCT04752358Lead sponsorPhase 2Sep 15, 2021
- NCT04408898Lead sponsorPhase 2Jun 30, 2020
- NCT06703346Lead sponsorPhase 2Dec 31, 2019
- NCT04044859Lead sponsorPhase 1Sep 30, 2019
- NCT04044768Lead sponsorPhase 2Aug 1, 2019
- NCT03168438Lead sponsorEarly Phase 1May 24, 2017
- NCT03132922Lead sponsorPhase 1May 15, 2017
- NCT03132792Lead sponsorPhase 1May 8, 2017
- NCT02992743Lead sponsorPhase 1/Phase 2Nov 1, 2016
- NCT02989064Lead sponsorPhase 1Oct 1, 2016
- NCT02588612Lead sponsorPhase 1/Phase 2Nov 1, 2015
Details
- Founded
- Oxton, GB Jun 1, 2008
- Last known activity
- Aug 1, 2024